JCO:辅助化疗对HER2阳性乳腺癌老年患者生活质量的影响

2021-04-10 Nebula MedSci原创

辅助化疗对HER2阳性乳腺癌老年患者生活质量的影响

过表达人表皮生长因子受体2(HER2)的乳腺癌(BC)具有侵袭性的临床病程。但是,抗HER2人源性单克隆抗体曲妥珠单抗的开发,显著改善了HER2阳性BC患者的预后。

本文报道了对HER2阳性乳腺癌老年人患者的生活质量(QoL)的研究结果,该试验比较了曲妥珠单抗辅助治疗和曲妥珠单抗联合化疗对乳腺癌老年患者生活质量的影响。

手术治疗后的70-80岁、HER2阳性的乳腺癌患者被随机分至曲妥珠单抗(T)组和曲妥珠单抗联合化疗组(T+C)。采用癌症综合治疗功能评估量表(FACT-G)、费城老年中心士气量表、医院焦虑抑郁量表、患者神经毒性问卷和东京都老年研究所胜任能力指数在基线和治疗后2、12、36个月进行生活质量评估。比较基于个体从基线开始的变化,并通过费舍尔检验或混合模型进行重复测量。

整体生活质量对比

在275位患者中,231位(84%)(平均 74岁)被纳入分析。在第2、12和36个月时分别有198、177和178位患者完成了调查问卷,T组在每个调查时间点(基线和治疗后2、12、36个月)的平均FACT-G得分分别为78.9、80.4、82.7和79.1分,T+C组的分别为79.5、74.5、78.4和78.5分。

与T+C组相比,T组患者在治疗2个月时的(31% vs 48%;p=0.016)和12个月时(19% vs 38%;p=0.009)出现生活质量恶化的患者比例(较基线下降≥5分)显著降低

T组在治疗2个月时的医院焦虑和抑郁量表得分(p=0.003)和严重感觉周围神经病变(p=0.001)的患者比例显著低于T+C组,而在12个月时费城老年中心士气量表和东京都老年学会能力指数得分显著高于T+C组。

在36个月时,在任何生活质量评估项目上都没有显著差异。

综上,辅助化疗对乳腺癌老年患者的整体生活质量、士气和活动能力的不利影响持续了至少12个月,但在36个月时没有再观察到

原始出处:

Taira Naruto,Sawaki Masataka,Uemura Yukari et al. Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer. J Clin Oncol, 2021, https://doi.org/10.1200/JCO.20.02751

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891646, encodeId=9aea1891646c3, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 12 18:45:38 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308592, encodeId=26a713085921d, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Apr 12 07:45:38 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955729, encodeId=48b7955e2923, content=了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d5479018, createdName=ms9000001550113929, createdTime=Sat Apr 10 18:21:42 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955718, encodeId=7fdc955e189a, content=太有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a14f5479026, createdName=魏加油, createdTime=Sat Apr 10 16:55:29 CST 2021, time=2021-04-10, status=1, ipAttribution=)]
    2021-12-12 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891646, encodeId=9aea1891646c3, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 12 18:45:38 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308592, encodeId=26a713085921d, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Apr 12 07:45:38 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955729, encodeId=48b7955e2923, content=了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d5479018, createdName=ms9000001550113929, createdTime=Sat Apr 10 18:21:42 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955718, encodeId=7fdc955e189a, content=太有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a14f5479026, createdName=魏加油, createdTime=Sat Apr 10 16:55:29 CST 2021, time=2021-04-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1891646, encodeId=9aea1891646c3, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 12 18:45:38 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308592, encodeId=26a713085921d, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Apr 12 07:45:38 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955729, encodeId=48b7955e2923, content=了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d5479018, createdName=ms9000001550113929, createdTime=Sat Apr 10 18:21:42 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955718, encodeId=7fdc955e189a, content=太有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a14f5479026, createdName=魏加油, createdTime=Sat Apr 10 16:55:29 CST 2021, time=2021-04-10, status=1, ipAttribution=)]
    2021-04-10 ms9000001550113929

    了解了解

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1891646, encodeId=9aea1891646c3, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 12 18:45:38 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308592, encodeId=26a713085921d, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Apr 12 07:45:38 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955729, encodeId=48b7955e2923, content=了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d5479018, createdName=ms9000001550113929, createdTime=Sat Apr 10 18:21:42 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955718, encodeId=7fdc955e189a, content=太有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a14f5479026, createdName=魏加油, createdTime=Sat Apr 10 16:55:29 CST 2021, time=2021-04-10, status=1, ipAttribution=)]
    2021-04-10 魏加油

    太有用

    0

相关资讯

BMC Med:反式脂肪酸摄入与乳腺癌风险的相关性

手里的薯条、爆米花还吃的下吗~

Br J Cancer:新辅助疗法治疗乳腺癌的回顾性观察研究

约15–20%的新确诊的浸润性乳腺癌(BC)患者表现出HER2(人类表皮生长因子受体2)蛋白的过表达,其一般是由于HER2基因的扩增所致的。

JCO:阿贝西利联合氟维司群对PIK3CA突变HR+/HER2-晚期乳腺癌患者效果良好

近日,JCO在线发表了一项III期SOLAR-1临床试验的患者报告结局。结果显示携带PIK3CA突变的激素受体阳性、人表皮生长因子受体2阴性、晚期乳腺癌患者接受阿贝西利+氟维司群联合治疗,耐受性良好。

中国自主创新微球制剂瑞欣妥®上市,以全球领先微球技术提升精神分裂症临床获益

3月27日,绿叶制药集团宣布其自主研发的抗精神分裂症新药——瑞欣妥?〔注射用利培酮微球(Ⅱ)〕正式在华上市。瑞欣妥?是中国首个具有自主知识产权并开展全球注册的创新微球制剂,同时

Br J Cancer:ABCSG-34临床试验揭示新辅助疗法对于乳腺癌的效果

对于局部晚期无法进行手术的乳腺癌患者可采用术前化疗策略。目前,全身性的新辅助疗法已成为一种标准选择,